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Abstract
Background The estrogen receptor alpha (ESR1) is a
mediator of estrogen response in the breast. The most
studied variants in this gene are the PvuII and XbaI
polymorphisms, which have been associated to lower
sensitivity to estrogen. We evaluated whether these poly-
morphisms were associated with breast cancer risk by
means of an association study in a population of Caucasian
postmenopausal women from the Rotterdam study and a
meta-analysis of published data.
Methods The PvuII and XbaI polymorphisms were
genotyped in 3,893 women participants of the Rotterdam
Study. Baseline information was obtained through a ques-
tionnaire. We conducted logistic regression analyses to
assess the risk of breast cancer by each of the ESR1
genotypes. Meta-analyses of all publications on these
relations were done by retrieving literature from Pubmed
and by further checking the reference lists of the articles
obtained.
Results There were 38 women with previously diagnosed
breast cancer. During follow-up, 152 were additionally
diagnosed. The logistic regression analyses showed no
difference in risk for postmenopausal breast cancer in
carriers of the PvuII or XbaI genotypes neither in overall,
incident or prevalent cases. No further evidence of a role of
these variants was found in the meta-analysis.
Conclusions Our results suggest that the ESR1 poly-
morphisms do not play a role in breast cancer risk in
Caucasian postmenopausal women.
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Introduction
Family history is one of the strongest risk factors for breast
cancer [1]. It has been shown that the heritability of this
disease is ~30% [2]. The most important determinants of
risk for breast cancer are related to endogenous hormone
levels and major reproductive events [3], thus, suggesting
that genes in the estrogen pathway may inﬂuence breast
cancer risk.
The estrogen receptor alpha (ESR1) is one of the most
important mediators of hormonal response in estrogen-
sensitive tissues such as the breast [4] and plays a crucial
role in breast growth and differentiation as well as in the
development of cancer [5]. The human ESR1 gene is
localized on chromosome 6q24-q27 [6], it extends more
than 140 kb and includes eight exons [7]. The most studied
variants in this gene are the PvuII (C/T) and XbaI (G/A)
polymorphisms in intron 1, 397 and 351 bp upstream of
exon 2 respectively [8, 9]. These variants have been
implicated in gene expression by inﬂuencing transcription
[10]. While some studies have found an increased risk for
the A and T alleles of the XbaI and PvuII polymorphisms [4,
9, 10], others have found an increased risk only for the X
(G) allele of XbaI [11, 12]. In addition, other studies found
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These alleles were correlated with high bone mineral den-
sity and height in other studies, including one performed in
our study population, [14, 15], suggesting a stronger
estrogenic effect in P(C) and X(G) allele carriers [14].
The aim of our study was to evaluate the effect of these
polymorphisms on breast cancer risk by performing an
association analysis in a population based study of Cau-
casian postmenopausal women. Further, we performed
meta-analyses of all available published data on these
polymorphisms and the risk of breast cancer.
Materials and methods
Study population and measurements
Our study population is part of the Rotterdam study [16].
Inhabitants of the suburb of Ommoord aged 55 or older
were invited to participate and 7983 agreed to do so (re-
sponse rate 78.1%). Study participants signed an informed
consent and the Medical Ethics Committee of the Erasmus
Medical Center approved the study. Our study group was
composed of 4,878 postmenopausal women. Information
on risk factors such as age at entry, age at menarche, age at
menopause, parity, body mass index (BMI), waist hip ratio
(WHR) and hormone replacement therapy use (HRT) was
retrieved at baseline through a questionnaire. BMI was
calculated by dividing the weight in kilograms by the
height (in meters) squared [17].
Case identiﬁcation and validation
Three different databases were used for patient identiﬁca-
tion. First, cases diagnosed by general practitioners in the
research area (Ommoord) were collected (International
Classiﬁcation of Primary Care (code X76)). Second, the
Dutch National Registry of all hospital admissions (LMR)
was consulted to detect all malignancy related hospital
admissions for study participants. Finally, regional
pathology databases were linked to the Rotterdam Study to
identify patients. Subsequently, breast cancer cases were
validated by a physician on the basis of medical records of
the general practitioner, discharge letters and pathology
reports. Only pathologically conﬁrmed cases were consid-
ered in the analysis. The index date was deﬁned as the
earliest date found in the pathology report.
Genotyping & data analysis
Out of the 4,878 women participating in our study, 3,893
(80 %) were successfully genotyped for the PvuII and XbaI
polymorphisms. The genotyping procedures have been
described previously [14]. Loss to follow up was assessed
to verify it was independent of genotype. Categorical
variables, such as parity and HRT, were compared between
genotype groups using the chi-squared test. Continuous
variables, (age at entry, age at menopause, BMI and WHR)
were compared using the independent sample Mann–
Whitney test. We used logistic regression to study the risk
of breast cancer by ESR1 genotype. This analysis was
performed using SPSS version 11, since there is no clear
risk allele from the literature, we took the TT (PvuII) and
AA (XbaI) genotypes as reference because they have been
associated to lower sensitivity to estrogen in our population
[14]. We also performed a trend test to evaluate if the
number of risk alleles carried had an effect on disease risk.
Hardy-Weinberg equilibrium (HWE) was assessed for both
polymorphisms using Markov-Chain Monte-Carlo
approximation of the exact test implemented in the
GENEPOP package V 3.3 [18].
Meta-analysis
We searched PubMed until October 2006 for all case-
control studies on the association of the PvuII and XbaI
polymorphisms in the ESR1 gene and breast cancer. Our
search strategy was based on the keyword ‘‘breast cancer’’
combined with ‘‘estrogen receptor’’ and ‘‘polymorphism’’.
To verify that all studies were retrieved, the reference lists
of all publications were searched for additional studies. We
excluded studies from our analyses if the genotype fre-
quencies in the control population were out of Hardy-
Weinberg or if their data had been previously used in an-
other study. To quantify the strength of association, pooled
odds ratios (ORs) and 95% conﬁdence intervals (CI) were
calculated using the random-effects model of the DerSi-
monian and Laird method [19]. The degree of heteroge-
neity between the study results was tested by the
inconsistency statistic (I
2). Funnel plots were used to
evaluate publication bias [20]. Data were analysed using
Review Manager, version 4.2 (Cochrane Collaboration,
Oxford, UK).
Results
The total loss of follow-up for the genotyped participants
was 8.4% and it was not dependent on ESR1 genotype
(P = 0.51). The genotype frequencies of both polymor-
phisms were in HWE proportions (X
2 P = 0.33 for PvuII
and X
2 P = 0.31 for XbaI). In Table 1 we show the baseline
characteristics of our study population. We found that all
cases (incident and prevalent) were signiﬁcantly younger at
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123entry than controls (P < 0.001) and also died earlier during
follow-up (P < 0.001), when using incident cases only we
found the same signiﬁcant differences (P for age at entry
<0.0001, P for age at death <0.0001). We also found that
cases had signiﬁcantly fewer children than controls
(P = 0.04). We did not ﬁnd any signiﬁcant differences in
these baseline characteristics between genotype groups
(data not shown).
There were 38 women with previously diagnosed post-
menopausal breast cancer who entered the study. During
follow-up, 152 were additionally diagnosed. There were no
signiﬁcant differences in the number of cases between the
PvuII (P = 0.43 for overall cases) and XbaI genotypes
(P = 0.33 for overall cases).
We carried out a logistic regression analysis adjusting
for age at entry, age at menopause, BMI, WHR and HRT
for both polymorphisms separately (Table 2). Since the T
and A alleles of these polymorphisms have been correlated
to lower estrogenic effects, we used the TT and AA
genotypes as our reference categories in the analyses.
There were no signiﬁcant differences in risk for breast
cancer among carriers of the different genotypes of the
PvuII or XbaI polymorphisms in the ESR1 gene. There was
a non-signiﬁcant tendency of the C allele of PvuII (P-for
trend = 0.22) and G allele of the XbaI (P-for trend 0.26) to
be over represented in patients.
To evaluate our data together with those in the literature
we performed meta-analyses. We identiﬁed nine articles
studying the relation between XbaI and PvuII polymor-
phisms and the risk of breast cancer [4, 9–12, 21–24]. We
excluded from our analyses one study [11], since the data
was used in another study [4]. Furthermore, two studies
were excluded since genotype frequencies of controls were
out of HWE proportions [9, 10]. Using the random effects
model we did not ﬁnd any difference in risk among XbaI
and PvuII genotypes (Figs. 1 and 2). High inter-study
heterogeneity can render the interpretation of the results of
a meta-analysis difﬁcult and although we found high het-
erogeneity in the G/A versus GG comparison there was no
signiﬁcant heterogeneity in the other three comparisons.
Additionally, the evaluation of the funnel plots did not
suggest evidence for publication bias.
Discussion
We performed an association study to evaluate the rela-
tionship of two well-studied polymorphisms in the ESR1
gene and the risk of breast cancer in Caucasian postmen-
opausal women from the Rotterdam Study. Using logistic
regression analysis, we found no evidence of effect, with
only a non-signiﬁcant increase in breast cancer risk for AA
carriers of the XbaI polymorphism (overall OR = 1.3, 95%
CI = 0.7–2.2) and for TT carriers of the PvuII variant
(overall OR = 1.4, 95% CI = 0.8–2.2). Additionally we
performed meta-analyses of published data to examine the
effect of both polymorphisms. These meta-analyses also
suggest there are no differences in risk among genotype
groups of these two ESR1 variants.
The XbaI and PvuII polymorphisms are situated in in-
tron 1 and their functionality has not yet been demon-
strated. Moreover, it has been suggested their effects could
be the result of high linkage disequilibrium with functional
variants that affect sensitivity to estrogen [13].
One of the limitations of our study is the limited number
of breast cancer cases present in our population. Never-
Table 1 General characteristics
of the study population
* P-value \ 0.05
Cases Controls Total
Total studied (%) 190 (4.7%) 3513 (95.3) 3703
Mean age of entry (SD)* 67.80 (7.7) 70.36 (9.6) 70.24 (9.6)
Mean age at death (SD)* 77.30 (8.6) 84.46 (8.7) 84.12 (8.8)
Mean age at menarche (SD) 13.57 (1.7) 13.68 (1.8) 13.67 (1.8)
Mean age at menopause (SD)* 49.51 (4.8) 52.19 (13.6) 52.07 (13.3)
Mean number of children (SD)* 1.77 (1.6) 2.12 (1.7) 2.10 (1.7)
Parity (SD) (‡1 child)* 121 (71.6) 2640 (79.4) 2761 (79)
Hormone replacement therapy(%) 27 (21.1) 504 (19.5) 531 (19.6)
Mean BMI (SD) 27.10 (3.9) 26.67 (4.1) 26.69 (4.1)
Mean WHR (SD) 0.87 (.09) 0.87 (.09) 0.87 (.09)
Table 2 Odds ratios for breast cancer risk for PvuII and XbaI
genotypes
Overall Incident Prevalent
PvuII
TT Ref Ref Ref
TC 0.9 (0.6–1.4) 1.0 (0.6–1.6) 0.8 (0.3–2.1)
CC 1.4 (0.8–2.2) 1.4 (0.8–2.5) 1.2 (0.4–3.3)
XbaI
AA Ref Ref Ref
GA 1.2 (0.8–1.7) 1.3 (0.8–2.0) 0.8 (0.4–1.9)
GG 1.3 (0.7–2.2) 1.5 (0.8–2.8) 0.5 (0.2–2.4)
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123theless, we have sufﬁcient power (b = 0.8) to detect effects
of 1.6 or higher. We further conducted meta-analyses off
all studies conducted to date. Our data suggests that these
two polymorphisms do not play a role in the susceptibility
of breast cancer in elderly Caucasian women.
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